SEARCH

SEARCH BY CITATION

References

  • 1
    Austin, C.A., Marsh, K.L., Wasserman, R.A., Willmore, E., Sayer, P.J., Wang, J.C., Fisher, L.M. (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. Journal of Biological Chemistry. 270, 15739 15746.
  • 2
    Beidler, D.R. & Cheng, Y.-C. (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Molecular Pharmacology. 47, 907 914.
  • 3
    Boege, F.A., Andersen, A.H., Jensen, S., Zeidler, R., Kreipe, H. (1995) Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. American Journal of Pathology. 146, 1302 1308.
  • 4
    Burden, D.A., Goldsmith, L.J., Sullivan, D.M. (1993) Cell-cycle-dependent phosphorylation and activity of Chinese hamster ovary topoisomerase II. Biochemical Journal. 293, 297 304.
  • 5
    Burden, D.A., Kingma, P.S., Froelich-Ammon, S.J., Bjornsti, M.-A., Patchan, M.W., Thompson, R.B., Osheroff, N. (1996) Topoisomerase II * etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. Journal of Biological Chemistry. 271, 29238 29244.
  • 6
    Burden, D.A. & Sullivan, D.M. (1994) Phosphorylation of the α- and β-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry. 33, 14651 14655.
  • 7
    Chapuis, J.-C., Keng, P.C., Siemann, D.W. (1992) Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures. Anti-Cancer Drugs. 3, 245 252.
  • 8
    Chow, K.-C. & Ross, W.E. (1987) Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Molecular and Cellular Biology. 7, 3119 3123.
  • 9
    Croix, B.S. & Kerbel, R.S. (1997) Cell adhesion and drug resistance in cancer. Current Opinions in Oncology. 9, 549 556.
  • 10
    Dang, Q., Alghisi, G.C., Gasser, S.M. (1994) Phosphorylation of the C-terminal domain of yeast topoisomerase II by casein kinase II affects DNA–protein interaction. Journal of Molecular Biology. 243, 10 24.DOI: 10.1006/jmbi.1994.1626
  • 11
    Drake, F.H., Zimmerman, J.P., McCabe, F.L., Bartus, H.F., Per, S.R., Sullivan, D.M., Ross, W.E., Mattern, M.R., Johnson, R.K., Crooke, S.T., Mirabelli, C.K. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. Journal of Biological Chemistry. 262, 16739 16747.
  • 12
    Estey, E., Adlakha, R.C., Hittelman, W.N., Zwelling, L.A. (1987) Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry. 26, 4338 4344.
  • 13
    Fairman, R. & Brutlag, D.L. (1988) Expression of the Drosophila type II topoisomerase is developmentally regulated. Biochemistry. 27, 560 565.
  • 14
    Furukawa, M., Uchiumi, T., Nomoto, M., Takano, H., Morimoto, R.I., Naito, S., Kuwano, M., Kohno, K. (1998) The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIα gene by heat shock. Journal of Biological Chemistry. 273, 10550 10555.
  • 15
    Gudkov, A.V., Zelnick, C.R., Kazarov, A.R., Thimmapaya, R., Suttle, D.P., Beck, W.T., Roninson, I.B. (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proceedings of the National Academy of Sciences of the United States of America. 90, 3231 3235.
  • 16
    Harker, W.G., Slade, D.L., Parr, R.L., Feldhoff, P.W., Sullivan, D.M., Holguin, M.H. (1995) Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Research. 55, 1707 1716.
  • 17
    Heck, M.M.S. & Earnshaw, W.C. (1986) Topoisomerase II: a specific marker for cell proliferation. Journal of Cell Biology. 103, 2569 2581.
  • 18
    Heck, M.M.S., Hittelman, W.N., Earnshaw, W.C. (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proceedings of the National Academy of Sciences of the United States of America. 85, 1086 1090.
  • 19
    Hirano, T. & Mitchison, T.J. (1993) Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus eggs extracts. Journal of Cell Biology. 120, 601 612.
  • 20
    Hochhauser, D., Valkov, N.I., Gump, J.L., Wei, I., O'hare, C., Hartley, J., Fan, J., Bertino, J.R., Banerjee, D., Sullivan, D.M. (1999) Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines. Journal of Cellular Biochemistry. 75, 245 257.
  • 21
    Holden, J.A., Rolfson, D.H., Wittwer, C.T. (1990) Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry. 29, 2127 2134.
  • 22
    Hsiang, Y.-H., Wu, H.-Y., Liu, L.F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Research. 48, 3230 3235.
  • 23
    Isaacs, R.J., Harris, A.L., Hickson, I.D. (1996) Regulation of the human topoisomerase IIα gene promoter in confluence-arrested cells. Journal of Biological Chemistry. 271, 16741 16747.
  • 24
    Kaufmann, S.H., McLaughlin, S.J., Kastan, M.B., Liu, L.F., Karp, J.E., Burke, P.J. (1991) Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Research. 51, 3534 3543.
  • 25
    Liu, L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry. 58, 351 375.
  • 26
    Liu, L.F., Rowe, T.C., Yang, L., Tewey, K.M., Chen, G.L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II. Journal of Biological Chemistry. 258, 15365 15370.
  • 27
    Markovits, J., Pommier, Y., Kerrigan, D., Covey, J.M., Tilchen, E.J., Kohn, K.W. (1987) Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Research. 47, 2050 2055.
  • 28
    Meyer, K.N., Kjeldsen, E., Straub, T., Knudsen, B.R., Hickson, I.D., Kikuchi, A., Kreipe, H., Boege, F. (1997) Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. Journal of Cell Biology. 136, 775 788.
  • 29
    Nakajima, T., Morita, K., Ohi, N., Arai, T., Nozaki, N., Kikuchi, A., Osaka, F., Yamao, F., Oda, K. (1996) Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. Journal of Biological Chemistry. 271, 24842 24849.
  • 30
    Nelson, E.M., Tewey, K.M., Liu, L.F. (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide . Proceedings of the National Academy of Sciences of the United States of America. 81, 1361 1365.
  • 31
    Nigg, E.A. (1997) Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature. 386, 779 787.
  • 32
    Qiu, J., Catapano, C.V., Fernandes, D.J. (1996) Formation of topoisomerase IIα complexes with nascent DNA is related to VM-26-induced cytotoxicity. Biochemistry. 35, 16354 16360.
  • 33
    Ritke, M.K., Murray, N.R., Allan, W.P., Fields, A.P., Yalowich, J.C. (1995) Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of βII protein kinase C. Molecular Pharmacology. 48, 798 805.
  • 34
    Robbie, M.A., Baguley, B.C., Denny, W.A., Gavin, J.B., Wilson, W.R. (1988) Mechanism of resistance of noncycling mammalian cells to 4′-(9-acridinylamino) methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures . Cancer Research. 48, 310 319.
  • 35
    Schneider, E., Darkin, S.J., Robbie, M.A., Wilson, W.R., Ralph, R.K. (1988) Mechanism of resistance of non-cycling mammalian cells to 4′-(9-acridinylamino) methanesulfon-m-anisidide: role of DNA topoisomerase II in log- and plateau-phase CHO cells . Biochimica et Biophysica Acta. 949, 264 272.
  • 36
    Sechler, J.L. & Schwarzbauer, J.E. (1998) Control of cell cycle progression by fibronectin matrix architecture. Journal of Biological Chemistry. 273, 25533 25536.
  • 37
    Smalheiser, N.R. (1996) Proteins in unexpected locations. Molecular Biology of the Cell. 7, 1003 1014.
  • 38
    Sugimoto, K., Yamada, K., Egashira, M., Yazaki, Y., Hirai, H., Kikuchi, A., Oshimi, K. (1998) Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells. Blood. 91, 1407 1417.
  • 39
    Sullivan, D.M., Glisson, B.S., Hodges, P.K., Smallwood-Kentro, S., Ross, W.E. (1986) Proliferation dependence of topoisomerase II mediated drug action. Biochemistry. 25, 2248 2256.
  • 40
    Sullivan, D.M., Latham, M.D., Ross, W.E. (1987) Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Research. 47, 3973 3979.
  • 41
    Sullivan, D.M., Latham, M.D., Rowe, T.C., Ross, W.E. (1989) Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry. 28, 5680 5687.
  • 42
    Sumner, A.T. (1996) The distribution of topoisomerase II on mammalian chromosomes. Chromosome Research. 4, 5 14.
  • 43
    Swedlow, J.R., Sedat, J.W., Agard, D.A. (1993) Multiple chromosomal populations of topoisomerase II detected in vivo by time-lapse, three-dimensional wide-field microscopy. Cell. 73, 97 108.
  • 44
    Taagepera, S., McDonald, D., Loeb, J.E., Whitaker, L.L., McElroy, A.K., Wang, J.Y.J., Hope, T.J. (1998) Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 95, 7457 7462.
  • 45
    Tricoli, J.V., Sahai, B.M., McCormick, P.J., Jarlinski, S.J., Bertram, J.S., Kowalski, D. (1985) DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T/2) cells. Experimental Cell Research. 158, 1 14.
  • 46
    Turley, H., Comley, M., Houlbrook, S., Nozaki, N., Kikuchi, A., Hickson, I.D., Gatter, K., Harris, A.L. (1997) The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. British Journal of Cancer. 75, 1340 1346.
  • 47
    Valkov, N.I. & Sullivan, D.M. (1997) Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Seminars in Hematology. 34, 48 62.
  • 48
    Wang, J.C. (1996) DNA topoisomerases. Annual Review of Biochemistry. 65, 635 692.
  • 49
    Wessel, I., Jensen, P.B., Falck, J., Mirski, S.E.L., Cole, S.P.C., Sehested, M. (1997) Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Research. 57, 4451 4454.
  • 50
    Whalen, A.M., McConnell, M., Fisher, P.A. (1991) Developmental regulation of Drosophila DNA topoisomerase II. Journal of Cell Biology. 112, 203 213.
  • 51
    Woessner, R.D., Mattern, M.R., Mirabelli, C.K., Johnson, R.K., Drake, F.H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation. 2, 209 214.